13F Holdings
中文EN

BNGO Bionano Genomics, Inc.

Laboratory Analytical Instruments · Nasdaq · SEC CIK 1411690 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY8.2%
TTM net income YoY22.0%
TTM EPS YoY84.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin48.0%
Operating margin-97.1%
Net margin-96.9%
FCF margin—
EBITDA margin-76.0%

Returns

ROE-77.2%
ROA-48.0%
ROIC (approx.)-67.6%
Asset turnover0.50x

Leverage & solvency

Liabilities / assets39.1%
Debt / equity0.00x
Current ratio2.07x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.63x
Accruals ratio-17.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$28.51M$30.78M$36.12M$27.80M$17.98M
Cost of revenue$15.32M$30.40M$26.55M$21.86M$14.11M
Gross profit$13.19M$380,000$9.57M$5.95M$3.87M
R&D expense$11.37M$24.80M$54.03M$49.05M$22.48M
SG&A expense$35.15M$51.85M$92.76M$88.60M$58.49M
Operating income-$33.34M-$103.98M-$215.25M-$131.70M-$77.10M
Interest expense——$5.12M$298,000$927,000
Pretax income-$26.33M-$111.98M-$232.43M-$130.71M-$78.15M
Income tax$67,000$33,000$62,000$1.88M-$5.72M
Net income-$26.39M-$112.02M-$232.49M-$132.60M-$72.44M
EBITDA-$23.81M-$89.96M-$201.54M-$122.08M-$73.75M
EPS (basic)-4.85-88.13-408.60-4.58-0.26
EPS (diluted)-4.85-88.13-408.60-4.58-0.26
Weighted avg. shares (diluted)5.45M1.27M569,00028.92M276.78M
Balance sheet
Cash & equivalents$2.99M$9.17M$17.95M$5.09M$24.57M
Short-term investments$16.28M$302,000$48.82M$108.09M$226.04M
Receivables$5.20M$4.75M$9.32M$7.02M$4.93M
Inventory$7.83M$13.28M$27.60M$29.76M$12.39M
Current assets$45.39M$39.49M$140.12M$157.30M$272.41M
PP&E, net$14.85M$19.22M$23.34M$18.03M$10.32M
Goodwill——$0$77.29M$56.16M
Intangibles$4.34M$9.71M$33.97M$41.14M$26.84M
Total assets$73.58M$76.67M$214.40M$307.50M$377.10M
Current liabilities$22.94M$37.34M$100.03M$35.88M$21.84M
Long-term debt————$0
Total debt————$0
Total liabilities$29.16M$41.30M$118.25M$58.10M$39.98M
Shareholders' equity$44.42M$35.38M$96.16M$249.40M$337.12M
Net debt————-$24.57M
Shares outstanding10.74M1.87M762,53329.72M289.60M
Cash flow statement
Operating cash flow-$16.34M-$68.92M-$125.18M-$124.82M-$71.93M
Investing cash flow-$12.75M$73.84M$24.16M$82.77M-$278.06M
Financing cash flow$24.04M-$13.69M$113.81M$23.01M$336.11M
Depreciation & amortization$9.53M$14.02M$13.71M$9.62M$3.35M
Stock-based compensation$4.53M$9.74M$15.18M$22.42M$9.72M

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.